Format

Send to

Choose Destination
Toxicol Lett. 2009 Apr 10;186(1):45-51. doi: 10.1016/j.toxlet.2008.10.014. Epub 2008 Oct 28.

The use of gene array technology and proteomics in the search of new targets of diseases for therapeutics.

Author information

1
Progenika Biopharma, S.A., Zamudio Technology Park, 48160 Derio, Vizcaya, Spain. mferrer@progenika.com

Abstract

The advent of functional genomics has been greatly broadening our view and accelerating our way in numerous medical research fields. The complete genomic data acquired from the human genome project and the desperate clinical need of comprehensive analytical tools to study complex diseases, has allowed rapid evolution of genomic and proteomic technologies, speeding the rate and number of discoveries in new biomarkers. By jointly using genomics, proteomics and bioinformatics there is a great potential to make considerable contribution to biomarker identification and to revolutionize both the development of new therapies and drug development process.

PMID:
19022361
DOI:
10.1016/j.toxlet.2008.10.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center